News

Bonumose Inc. to invest $27.7M in Albemarle County expansion

Virginia sugar alternatives company Bonumose Inc. will invest $27.7 million to expand in Albemarle County in a partnership with The Hershey Co. to research and develop reduced or zero sugar chocolate products, creating 64 jobs, Gov. Ralph Northam announced.

Bonumose will move into 36,000 square feet of the former State Farm building to increase production capabilities and relocate its research and development lab from North Fork — A University of Virginia Discovery Park, an industrial park in Charlottesville.

“We are thrilled to celebrate the growth of Bonumose as it expands production and collaborates with other valued partners in the commonwealth,” Northam said in a statement. “This innovative company continues to advance our food and beverage processing industries. We look forward to a long and productive partnership with the company.”

Founded in 2016, Bonumose has developed and patented methods for continuous production of high-purity rare sugars like tagatose and allulose. The sugars come from starch byproduct left over from the company’s supply chain partners’ food production. Bonumose is also working on enzyme solutions for dietary supplements, crop protection, animal nutrition and other industries. In February, it announced the closing of Series B investments co-led by Hershey and American Sugar Refining Inc., the owner of the Domino sugar brand.

The region’s skilled workforce and access to the Port of Virginia have helped the company grow, Bonumose CEO and co-founder Ed Rogers said.

“Virginia, and more specifically, Albemarle County, has been important to Bonumose’s growth to date,” Rogers said in a statement. “The commonwealth’s leading research universities, thriving food production industry, natural beauty and quality of life in Central Virginia are second-to-none. Due to Bonumose’s business partners in other states and other countries, we have had opportunities to grow outside Virginia, but we are happy with our choice to deepen our roots here at home.”

The Virginia Economic Development Partnership worked with Albemarle County and the Central Virginia Partnership to secure the project, for which Virginia competed with Florida, Idaho and North Dakota. Northam approved a $256,000 grant from the Commonwealth’s Opportunity Fund to assist Albemarle County. The company received a $300,000 grant from the Virginia Investment Performance Grant, an incentive for existing companies to continue capital investment. Bonumose is eligible to receive benefits from the Port of Virginia Economic and Infrastructure Development Zone Grant Program. The VED’s Virginia Jobs Investment Program will provide funding to support employee recruitment and training activities.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation